Stephen Faraone

Stephen Vincent Faraone (born July 27, 1956)^[1] is an American psychologist. He has worked mainly on attention-deficit hyperactivity disorder and related disorders and is considered one of the most influential psychologists in the world.^[2]

Stephen V. Faraone
Faraone in 2018
Born	(1956-07-27) July 27, 1956 (age 67) Babylon, New York, USA
Nationality	American
Alma mater	State University of New York at Stony Brook (B.A.) University of Iowa (Ph.D.) Brown University (Internship & Post Doctoral Programs)
Known for	Research into the nature, causes and treatment of ADHD
Awards	CHADD Hall of Fame, Chancellor's Award for Excellence in Scholarship and Creative Activities from the State University of New York, Alumni Fellow status at the University of Iowa.
Scientific career
Fields	Child psychology and psychiatry
Institutions	Harvard Medical School Massachusetts General Hospital State University of New York Upstate Medical University
Doctoral advisor	Richard Hurtig, Ph.D.

Education and career

Faraone graduated in 1978 from the State University of New York at Stony Brook with a BA in Psychology. He then went to the University of Iowa where he obtained his Master of Arts and Doctor of Philosophy.^[3] Faraone completed a postdoctoral clinical psychology internship and a research fellowship at Brown University.^[4]

After completing his post-doctoral fellowship at Brown, Faraone came to the Harvard Department of Psychiatry, where he began a career in psychiatric genetics. He first served as an instructor in 1985, and as an assistant professor in 1989. He was promoted to associate professor in 1993 and Full Professor in 2002. In 2004, he moved to SUNY Upstate Medical University where he is now Distinguished Professor of Psychiatry and of Neuroscience and Physiology.^[5] He is also Senior Scientific Advisor to the Research Program Pediatric Psychopharmacology at the Massachusetts General Hospital^[6] and a lecturer at Harvard Medical School. Faraone has been principal investigator on several National Institutes of Health -funded grants studying the nature and causes of mental disorders in childhood. He is one of the world's leading authorities on the genetics of psychiatric disorders and has also made substantial contributions to research in psychopharmacology and research methodology. He led the International Consensus Statement on ADHD,^[7] and heads The ADHD Evidence Project, which curates evidence-based information about ADHD.^[8]

Awards and honors

Faraone has authored over 700 journal articles,^[9] editorials, chapters, and books, and was the eighth-highest producer of High Impact Papers in Psychiatry from 1990 to 1999 as determined by the Institute for Scientific Information (ISI).^[10] In 2005, ISI determined him to be the second-highest cited author in the area of ADHD^[11] and in 2007, he was the third most highly cited researcher in psychiatry^[12] for the preceding decade. From 2014 to 2021 he has been listed as a highly cited researcher by Thomson Reuters/Clarivate Analytics.  In 2019 and 2020, his citation metrics placed him in the top 0.01% of scientists across all fields.^[13]

In 2002, Faraone was inducted into the CHADD Hall of Fame in recognition of outstanding achievement in medicine and education research on attention disorders. In 2004 and 2008, Faraone was elected Vice President of the International Society of Psychiatric Genetics and in 2019 he received the Paul Hoch Award from the American Psychopathological Association. In 2008, he received the SUNY Upstate President's Award for Excellence and Leadership in Research.^[14] In 2019 he was elected President of the World Federation of ADHD ^[15] In 2022 he was elected to the Norwegian Academy of Science and Letters.

Research Funding and Financial Disclosures

Faraone's research has been funded by the U.S. National Institute of Health, the European Union and the following companies: Otsuka, Shire/Takeda, Ironshore, McNeil, Janssen and Supernus. He has received income or potential income from Aardvark, Rhodes, OnDosis, Oysta, Sky Therapeutics, AIMH, Tris, Otsuka, Arbor, Ironshore, KemPharm/Corium, Akili, Supernus, Shire/Takeda, Atentiv, Noven, Axsome, Johnson & Johnson/Kenvue and Genomind. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. These disclosures are routinely reported in relevant publications^[16]

Books published

• Tsuang MT, Faraone SV. The Genetics of Mood Disorders, Baltimore, MD: Johns Hopkins; 1990
• Faraone SV, Tsuang, D, Tsuang MT. Genetics of Mental Disorders: A Guide for Students, Clinicians, and Researchers, New York, NY: Guilford;1999.
• Faraone, S.V. Straight Talk About Your Child’s Mental Health: What To Do When Something Seems Wrong, New York, NY: Guilford, 2003.
• Tsuang MT, Faraone SV & Glatt SG Schizophrenia: The Facts, Oxford University Press; 2011.
• Faraone, S.V. & Antshel, K. ADHD: Non-Pharmacologic Interventions Elsevier, 2014

References

1. "Stephen Faraone CV" (PDF). SUNY Upstate. Retrieved 4 February 2019.
2. "SUNY Upstate professor named 80th best scientist in the world | Upstate News | SUNY Upstate Medical University". www.upstate.edu. Retrieved 2024-03-26.
3. Psychiatry | SUNY Upstate Medical University
4. Psychiatry | SUNY Upstate Medical University
5. "Faculty:Psychiatry:SUNY Upstate Medical University". Retrieved 2009-05-10.
6. . Archived from the original on June 27, 2008. Retrieved 2009-05-10.
7. - Link to International Consensus Statement on ADHD
8. - Link to ADHD Evidence Project
9. Publications - link to PubMed
10. Science, 2000, Vol 288, pg 959
13. Ioannidis, John P. A.; Baas, Jeroen; Klavans, Richard; Boyack, Kevin W. (2019-08-12). "A standardized citation metrics author database annotated for scientific field". PLOS Biology. 17 (8): e3000384. doi:10.1371/journal.pbio.3000384. ISSN 1545-7885. PMC 6699798. PMID 31404057.
14. "Stephen Faraone". SUNY Upstate. Retrieved 4 February 2019.
15. "Board of the ADHD World Federation". www.adhd-federation.org. Retrieved 2020-12-16.
16. https://apsard.org/wp-content/uploads/2022/06/2022-APSARD-DISCLOSURE-REPORT.pdf ^{[bare URL PDF]}